These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 29881259)

  • 1. Incidence and risk of cardiac toxicities in patients with relapsed and refractory multiple myeloma treated with carfilzomib.
    Zhao F; Yang B; Wang J; Zhang R; Liu J; Yin F; Xu W; He C
    Drug Des Devel Ther; 2018; 12():1525-1531. PubMed ID: 29881259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiotoxicity of Carfilzomib in Two Japanese Patients with Relapsed Multiple Myeloma.
    Ikoma T; Saotome M; Sano M; Suwa K; Naruse Y; Ohtani H; Urushida T; Nagata Y; Ono T; Maekawa Y
    Intern Med; 2019 Jun; 58(11):1577-1581. PubMed ID: 30713316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis.
    Shah C; Bishnoi R; Jain A; Bejjanki H; Xiong S; Wang Y; Zou F; Moreb JS
    Leuk Lymphoma; 2018 Nov; 59(11):2557-2569. PubMed ID: 29465266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Cardiovascular Toxicity Associated with Treatments Containing Proteasome Inhibitors in Multiple Myeloma Therapy.
    Iannaccone A; Bruno G; Ravera A; Gay F; Salvini M; Bringhen S; Sabia L; Avenatti E; Veglio F; Milan A
    High Blood Press Cardiovasc Prev; 2018 Jun; 25(2):209-218. PubMed ID: 29582365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials.
    Chari A; Stewart AK; Russell SD; Moreau P; Herrmann J; Banchs J; Hajek R; Groarke J; Lyon AR; Batty GN; Ro S; Huang M; Iskander KS; Lenihan D
    Blood Adv; 2018 Jul; 2(13):1633-1644. PubMed ID: 29991494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of carfilzomib in the treatment of relapsed and (or) refractory multiple myeloma: a meta-analysis of data from clinical trials.
    Chen R; Chen B; Zhang X; Gao C
    Discov Med; 2016 Oct; 22(121):189-199. PubMed ID: 27875670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral neuropathy experience in patients with relapsed and/or refractory multiple myeloma treated with carfilzomib.
    Martin TG
    Oncology (Williston Park); 2013 Dec; 27 Suppl 3():4-10. PubMed ID: 25184230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
    Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
    Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and management of renal adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
    Shah JJ
    Oncology (Williston Park); 2013 Dec; 27 Suppl 3():19-23. PubMed ID: 25184232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
    Thompson JL
    Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Papadopoulos KP; Siegel DS; Vesole DH; Lee P; Rosen ST; Zojwalla N; Holahan JR; Lee S; Wang Z; Badros A
    J Clin Oncol; 2015 Mar; 33(7):732-9. PubMed ID: 25225420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma.
    Grandin EW; Ky B; Cornell RF; Carver J; Lenihan DJ
    J Card Fail; 2015 Feb; 21(2):138-44. PubMed ID: 25433360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis.
    Waxman AJ; Clasen S; Hwang WT; Garfall A; Vogl DT; Carver J; O'Quinn R; Cohen AD; Stadtmauer EA; Ky B; Weiss BM
    JAMA Oncol; 2018 Mar; 4(3):e174519. PubMed ID: 29285538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma.
    Steele JM
    J Oncol Pharm Pract; 2013 Dec; 19(4):348-54. PubMed ID: 23292972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Carfilzomib-Associated Cardiac Adverse Events.
    Mikhael J
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):241-5. PubMed ID: 26907720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carfilzomib Induced Tumor Lysis Syndrome and Other Adverse Events.
    Sandy EB; Weerasinghe C; Terjanian T
    J Pharm Pract; 2020 Apr; 33(2):213-216. PubMed ID: 30278813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the "real world".
    Mian HS; Fiala MA; Sanchez L; Vij R; Wildes TM
    Ann Hematol; 2021 May; 100(5):1261-1266. PubMed ID: 33475778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial.
    Lee JH; Park Y; Kang KW; Lee JJ; Lee HS; Eom HS; Do YR; Kim JS; Yoon SS; Shin DY; Koh Y; Kim KH; Lee WS; Jo JC; Lee YJ; Lee JY; Kim DS; Shim H; Chang MH; Kim SH; Min CK;
    Ann Hematol; 2021 Aug; 100(8):2051-2059. PubMed ID: 33447888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of hematologic adverse events in patients with relapsed and/or refractory multiple myeloma treated with single-agent carfilzomib.
    Nooka AK
    Oncology (Williston Park); 2013 Dec; 27 Suppl 3():11-8. PubMed ID: 25184231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and Management of Carfilzomib-induced Cardiovascular Toxicity; A Systematic Review and Meta-analysis.
    Latif A; Kapoor V; Lateef N; Ahsan MJ; Usman RM; Malik SU; Ahmad N; Rosko N; Rudoni J; William P; Khouri J; Anwer F
    Cardiovasc Hematol Disord Drug Targets; 2021; 21(1):30-45. PubMed ID: 33845729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.